Quick Answer
Enliven Therapeutics, Inc. reported Cash and Equivalents of $98.90 million for fiscal year 2025.
Enliven Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $98.90M | -20.3% |
| 2024 | $124.12M | +23.9% |
| 2023 | $100.14M | +32.6% |
| 2022 | $75.54M | +56.4% |
| 2021 | $48.31M | +1.3% |
| 2020 | $47.70M | +866.3% |
| 2019 | $4.94M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $101.73M | +1.1% | -14.8% |
| June 30, 2025 | $119.44M | +23.3% | +17.4% |
| March 31, 2025 | $101.70M | -31.8% | -18.1% |
| December 31, 2024 | $124.12M | +23.9% | +23.4% |
| September 30, 2024 | $100.62M | +36.3% | +3.9% |
| June 30, 2024 | $96.87M | -22.9% | -35.1% |
| March 31, 2024 | $149.16M | -48.9% | +49.0% |
| December 31, 2023 | $100.14M | +32.6% | +35.6% |
- Enliven Therapeutics, Inc. showed a decrease of -20.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Enliven Therapeutics, Inc.’s cash and equivalents has grown by 1903.6% (from $4.94 million to $98.90 million).
- The most recent figure is from Enliven Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: